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The majority of bronchogenic carcinomas can be histologically
classified into four types: small-cell lung carcinomas, adenocarci-
nomas, squamous cell lung carcinomas and large-cell carcinomas.
The histological features, clinical course and response to therapy
indicate that small-cell lung carcinomas are a separate entity. The
behaviour of the other three histological subtypes is similar.
Therefore, these are combined within the larger group of non-
small-cell lung carcinomas (NSCLCs). NSCLCs represent 75% of
all cases of lung cancer and are usually associated with a poor
prognosis. The present investigation is limited to NSCLC. In addi-
tion to pertinent clinical data, new risk factors at the molecular and
cellular level are the subject of many ongoing studies. Predictive
and prognostic factors can serve many purposes. They are used to
understand the natural history of cancer, to identify homogeneous
patient populations, to characterize subsets of patients with a
potentially favourable or unfavourable outcome, to predict the
success of therapy or to generate follow-up strategies.
It is a characteristic of all tumours to grow. However, tumours
are complex cell populations in which cell gain and loss occur
concurrently. In this investigation we analysed the relationship
between patient survival and the proliferative activity and
apoptosis in 150 NSCLCs in order to ascertain the implications of
these factors for the prognosis of the patients.
A variety of cellular changes can be used to evaluate cell prolif-
eration in tumour material. Cyclins and cyclin-dependent kinases
(cdks) are universal regulators of cellular progression in eukary-
otic cells (Lew and Kornbluth, 1996). Regulatory mechanisms
include variations in cyclin abundance, phosphorylation of the
kinase subunit that may yield either positive or negative effects
and the actions of cyclin-kinase inhibitory proteins. Several
classes of mammalian cyclins that are synthesized in various ways
and degraded at specific points during the cell cycle have been
described (Cordon-Cardo, 1995). The complex formed by cyclin
D1 and cdk4 governs the G1 progression, while cyclin A together
with cdk2 regulates entry into and progression through the S
phase. Another marker is the proliferating cell nuclear antigen
(PCNA) which is essential for cellular DNA synthesis. (Jashulski
et al, 1988; Garcia et al, 1989). In this study we examined the
prognostic value of cyclin A, cyclin D, cdk2, cdk4 and PCNA
through immunohistochemical analysis. Additionally we deter-
mined the cell cycle phases by using flow cytometry.
Apoptosis or programmed cell death is one of the most impor-
tant regulatory mechanisms of cellular homeostasis in organisms.
In this investigation we employed immunohistochemistry to deter-
mine the pro-apoptotic factors Fas/CD95, Fas ligand and caspase-
3. Fas is a transmembrane protein (receptor) which, upon binding
to its ligand (Fas ligand), transmits an intracellular signal that
leads to programmed cell death (Fisher, 1994; Nagata and
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Fas expression was 86 weeks and of those without Fas expression only 69 weeks. Corresponding results were obtained with the Fas ligand
(87 vs 41 weeks) and caspase 3 (87 vs 34 weeks). In order to determine whether a combination of factors can yield improved prognostic
information, we investigated all possible combinations of the proliferative and apoptotic factors. Patients with tumours having a high
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DOI: 10.1054/ bjoc.1999.1210, available online at http://www.idealibrary.com on Golstein, 1995). As previously reported, Fas and Fas ligand are
expressed in different tissues including lung cancer (Hellquist
et al, 1997; Niehans et al, 1997; Xerri et al, 1997). Caspases are
key effectors of cellular death. Of the caspases, caspase-3 (also
known as CPP32, Yama or apopain) is probably the one that so far
best correlates with apoptosis (Fernandez-Alnemri et al, 1994;
Nicholson et al, 1995).
The main purpose of the current study was to initially discover
the most important prognostic factors for NSCLCs and then to
examine whether a combination of proliferative and apoptotic
factors can result in improved prognostic information for overall
patient survival.
MATERIALS AND METHODS
Patients
One hundred and fifty patients with previously untreated NSCLC
were admitted into this study. All patients (135 men, 15 women)
underwent surgery in the Chest Hospital Heidelberg-Rohrbach.
The morphological classification of the carcinomas was conducted
according to World Health Organization (WHO) specifications. 
Of the carcinomas, 85 (56.6%) were squamous carcinomas, 40
(26.7%) were adenocarcinomas and 25 (16.7%) were large-cell
carcinomas. All patients were staged at the time of their surgery
according to the guidelines of the American Joint Committee on
Cancer. Thirty-two patients had stage I, 11 stage II and 107 patients
had stage IIIA tumours. The average age of the patients was 58
(range 25–76) years. Sixty-three patients (42%) did not exhibit
lymph node involvement while 87 did (58%). One hundred and
nine patients were given only surgical treatment. Fifteen patients
were also given cytotoxic drugs and 25 patients (mainly squamous
cell lung carcinomas) were treated with palliative irradiation. The
additional radiation treatment and chemotherapy had no signifi-
cant effect on overall patient survival time (P > 0.1). Follow-up
data were obtained from hospital charts and by corresponding with
the referring physicians.
Antibodies
To detect the proliferative activity, anti-cyclin A (clone H-432,
dilution 1:50), anti-cdk2 (clone M2, dilution 1:200) and anti-cdk4
(clone C-22, dilution 1:100) were used. These were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-
cyclin D1 (clone Ab-3, dilution 1:10) was produced by
Calbiochem/Novabiochem (Baden-Soden, Germany) and the
PCNA (clone PC10, dilution 1:10) was obtained from Dianova
(Hamburg, Germany). The antibody to detect the apoptotic factor
Fas (clone UB2, dilution 1:100) originated from Immunotech
(Hamburg, Germany) and the antibodies to detect the apoptotic
factors Fas ligand (clone Q20, dilution 1:500) and caspase-3
(clone CPP32 p20 [E-8], dilution 1:500) were products of Santa
Cruz Biotechnology.
Immunohistochemistry
The previously described biotin–streptavidin method was used to
detect the proteins (Volm et al, 1993, 1997b; Koomägi and Volm,
1999). Formalin-fixed and paraffin-embedded tissue were
deparaffinized and subsequently microwaved in citrate buffer.
After preincubation with hydrogen peroxide, and protein blocking
solution, the primary antibodies were applied for 16 h at 4°C.
After incubation with secondary antibodies, the streptavidin
biotinylated peroxidase complex was added and the peroxidase
activity visualized with 3-amino-9-ethylcarbazole. Counter-
staining was performed with haematoxylin. Negative and positive
controls were performed. The specificity of the antibodies was
confirmed by immunoblotting. Without having any prior knowl-
edge of each patient’s clinical data, three observers independently
evaluated the results from the immunohistochemical staining. If
the evaluations did not agree (< 10%) the specimens are reevalu-
ated and then classified according to the assessment given most
frequently by the observers. The immunohistochemical staining
was analysed according to a scoring method that we have previ-
ously validated in a series of animal and human cell lines and
human solid tumours. Finally, we classified the tumours into four
groups: tumours without staining and tumours with weak,
moderate and strong staining.
Western blot analysis
Protein was isolated with the Tri-reagent (MRC, Cincinnati, OH,
USA). After electrophoresis on a 12% polyacrylamide gel in the
presence of sodium dodecyl sulphate (SDS) and transfer to a
polyvinyl difluoride (PVDF) membrane (NEN, Boston, MA,
USA) by electroblotting, the transferred protein and molecular
weight markers were detected with 0.3% Ponceau S. Blocking 
in 1% blocking solution (Western Blocking Reagent, Boehringer
Mannheim, Germany) preceded the 1-h-long incubation with the
antibody diluted in 0.5% blocking solution. Thereafter, peroxi-
dase-conjugated streptavidin secondary antibodies (Santa Cruz)
were used to detect the proteins. All incubations were conducted
at room temperature and several washing steps followed each
incubation. Signals were detected with chemiluminescence or with
4-chloro-1-naphthol.
Cell cycle analysis
A mixture of propidium iodide and 4¢-6-diamidino-2-phenylindole
was applied simultaneously with RNAase after methanol fixation
and protease digestion of single cell suspensions (Haag, 1980).
Flow cytometry analysis was undertaken with an ICP-22 (Phywe,
Göttingen, Germany). Peripheral blood leucocytes from healthy
donors were used as a calibration standard for DNA diploidy.
Parallel measurements, both including and omitting the standard,
were performed. The cell cycle analysis was performed using inte-
grated Gaussian fittings. A computerized subtraction of exponen-
tially decreasing corrections beginning with the peak of cellular
debris was included in the evaluation program. The cell cycle
analysis was omitted in cases that exhibited interspersed cell
populations.
Statistical analysis
Patient survival time was determined from the date of surgery until
the last follow-up visit or reported death and was evaluated by
using life table analyses according to the method of Kaplan and
Meier. Groups were compared by using the log-rank test. The
correlations between clinical and molecular parameters were
statistically evaluated by using Fisher’s exact test. This test was
used as a statistical hypothesis test for the presence or absence
of a relationship between two factors. A P-value of < 0.05 was
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staining and tumours with weak staining were classified as nega-
tive and tumours with moderate to strong staining were classified
as positive.
RESULTS
Immunohistochemistry was used to determine the proliferative
factors PCNA, cyclin A, cyclin D1, cdk2, cdk4 and the pro-
apoptotic factors Fas, Fas-ligand and caspase-3 in formalin-fixed,
paraffin-embedded specimens from 150 NSCLCs of previously
untreated patients. Figure 1 shows representative protein expres-
sion patterns of PCNA (Figure 1A), cyclin A (Figure 1B), Fas
(Figure 1C) and caspase-3 (Figure 1D) which reveal nuclear
(PCNA, cyclin A), membrane (Fas) or cytoplasmatic (caspase-3)
immunoreactivity. The specificity of the staining was confirmed
by Western blots (Figure 2). DNA histograms representative of our
experimental data are shown in Figure 3.
Clinical prognostic factors
The overall survival of patients with NSCLCs is mainly deter-
mined by tumour extent, lymph node status and stage. This also
applies to our patients (Figure 4 and Table 1).
Cellular prognostic factors
In order to discover new prognostic factors at the cellular level, we
determined the expression of different proliferative factors in
NSCLCs. We then detected a relationship between patient survival
and the proliferative factors. Patients with PCNA-positive carci-
nomas had significantly shorter survival times than patients with
PCNA-negative carcinomas (51 vs 89 weeks, Table 2). The
relative risk for patients with PCNA-positive carcinomas was 
1.5 compared to patients with PCNA-negative carcinomas.
Corresponding results were obtained with the factors cyclin A,
with the factor cdk2, and with the factor cdk4 (Table 2). To
confirm these results, we used flow cytometry to analyse the S
phase proportion of the lung carcinomas. Consistent with the data
obtained by immunohistochemistry, we found that the survival
times were shorter for cancer patients with a high S phase propor-
tion than for patients with low S phase tumours (Table 2). In
contrast, no correlation was found between the expression of
cyclin D1 and a patient’s outcome.
Apoptosis is regulated by a variety of pro-apoptotic and anti-
apoptotic factors. In this study, we measured the pro-apoptotic
factors Fas, Fas ligand and caspase-3 and discovered an inverse
relationship between the apoptotic factors and patient survival.
Patients with a greater expression of the apoptotic factors had a
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Figure 1 Immunohistochemical staining of PCNA (A), cyclin A (B), Fas (C) and caspase-3 (D)more favourable prognosis. The median survival times of cancer
patients with Fas expression was 86 weeks and of those without
Fas expression only 69 weeks (Table 3). The relative risk estimate
for patients with Fas-negative carcinomas was 1.5 compared to
patients with Fas-positive carcinomas. Corresponding results were
obtained with the Fas ligand. Additionally, we analysed the rela-
tionship between caspase-3 and patient survival, because caspases
are key effectors of cellular death and, of the various caspases,
caspase-3 is the one that so far best correlates with apoptosis.
Analogous to the findings with Fas and Fas ligand, we determined
that patients who expressed caspase-3 had a favourable outcome
(Table 3).
Combinations of factors
An analysis of the inter-relationships of the cellular factors indi-
cated that a correlation does not exist among the proliferative and
the apoptotic factors (data not shown). In order to determine
whether a combination of factors can yield improved prognostic
information, we investigated all possible combinations of the
proliferative and apoptotic factors. Figures 5 to 8 show the results
of the combinations of the different proliferative factors and the
pro-apoptotic factor Fas. Patients with tumours having a high
proliferative activity, but which did not express Fas had the
shortest survival times while patients with a low proliferative
activity and a high expression of Fas had the most favourable
outcome. In Table 4 the median survival times and the relative
risks of patients grouped according to the proliferative activity and
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Figure 3 Representative examples of the DNA-histograms of lung
carcinomas. Cell cycle analysis was performed in areas marked by
darkening. CV = coefficient of variation
Figure 2 Immunoblot analyses (Western blots) of the carcinomas Nos. 12,
22, 28, 29. Detection of PCNA, cyclin A, Fas and caspase-3. PCNA, cyclin A
and caspase-3 were detected by chemoluminescence; Fas was detected by
4-chloro-1-naphthol.
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Figure 4 Survival curves (Kaplan–Meier estimates) of patients with NSCLC
grouped according to stage (above) and lymph node involvement (below)the level of carcinoma Fas expression are listed. The median
survival time of patients with PCNA-positive/Fas-negative carci-
nomas was only 19 weeks while the median survival time of
patients with PCNA-negative/Fas-positive carcinomas was 146
weeks. The relative risk for the first group of patients was 2.6.
Corresponding results were obtained with the other combinations
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Table 1 Median survival times (MST) and relative risk of patients with non-small cell lung carcinomas according to
clinical variables (n = 150)
Clinical variables Patients/ MST Log-rank Relative
death (weeks) Test risk
P-value
Tumour extent
T1,2 56/34 107 1.0
T3 94/73 65 0.021 1.6
LN involvement
Negative 63/38 141 1.0
Positive 87/69 43 0.0008 1.9
Stage
I, II 43/25 129 1.0
IIIA 107/82 65 0.014 1.7
Table 2 Median survival times (MST) and relative risk of patients with NSCLCs according to proliferative factors
Proliferative Patients/ MST Log-rank Relative
factors death (weeks) test risk
P-value
PCNA
Negative 99/67 89 1.0
Positive 43/34 51 0.049 1.5
Cyclin A
Negative 65/41 92 1.0
Positive 75/58 64 0.089 1.4
Cyclin D1
Negative 60/42 77 1.0
Positive 85/61 84 0.864 1.0
cdk2
Negative 39/26 89 1.0
Positive 105/76 76 0.362 1.2
cdk4
Negative 80/53 102 1.0
Positive 59/44 62 0.135 1.4
S phases
< 9.5% 32/19 121 1.0
> 9.5% 39/29 86 0.147 1.5
Tumour material was not available for all measurements. The cell cycle analysis was omitted in cases that exhibited
interspersed cell populations.
Table 3 Median survival times (MST) and relative risk of patients with NSCLCs according to apoptotic factors
Apoptotic Patients/ MST Log-rank Relative
factors death (weeks) test risk
P-value
Fas/CD95
Negative 71/58 69 1.5
Positive 78/48 86 0.022 1.0
Fas ligand
Negative 37/31 41 1.6
Positive 90/62 87 0.049 1.0
Caspase-3
Negative 26/20 34 1.5
Positive 69/49 87 0.157 1.0
Tumour material was not available for all measurements.(Table 4). Similar results were obtained with the proliferative
factors and the apoptotic factors Fas ligand and caspase-3 (data not
shown).
A multivariate analysis (Cox model) of the cellular and clinical
prognostic factors indicated that stage, lymph node involvement,
Fas, PCNA and cyclin A are the most important prognostic factors
for the clinical outcome of patients with NSCLCs. Since a very
high correlation exists between stage and lymph node involvement
and between PCNA and cyclin A, these factors have been con-
sidered separately (Table 5). Along with stage, the pair Fas and
PCNA gives the best prognostic separation. Along with lymph
node involvement, the pairs Fas/PCNA and Fas/cyclin A give the
best prognostic information.
DISCUSSION
In addition to established factors such as the extent of a tumour,
lymph node involvement and the particular stage of the disease in
lung carcinomas, the search for new risk factors is an ongoing
undertaking. The balance between proliferation and apoptosis
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Table 4 Median survival times (MST) and relative risk of patients with NSCLCs according to proliferative and
apoptotic factors
Combinations Patients/ MST Log-rank Relative
death (weeks) test risk
P-value
PCNA-pos/Fas-neg 18/16 19 2.6
PCNA-neg/Fas-pos 49/27 146 0.002 1.0
Cyclin A-pos/Fas-neg 31/28 77 2.7
Cyclin A-neg/Fas-pos 31/15 > 260 0.001 1.0
Cdk4-pos/Fas-neg 28/23 38 2.0
Cdk4-neg/Fas-pos 42/23 184 0.016 1.0
S phase high/Fas neg 18/16 38 3.0
S phase low/Fas-pos 18/8 > 260 0.007 1.0
Table 5 Multivariate analyses of the prognostic value of stage or lymph node involvement and the cellular
factors Fas, PCNA and cyclin A
Variables P-values Variables P-values
Stage 0.009 LN 0.001
Fas 0.007 Fas 0.026
PCNA 0.042 PCNA 0.040
Stage 0.016 LN 0.003
Fas 0.0008 Fas 0.033
Cyclin A 0.097 Cyclin A 0.046
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Figure 5 Survival times of patients (Kaplan–Meier estimates) with NSCLCs
according to the expression of a proliferative (PCNA) and an apoptotic factor
(Fas)
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Figure 6 Survival times of patients (Kaplan–Meier estimates) with NSCLCs
according to the expression of a proliferative (cyclin A) and an apoptotic
factor (Fas)within a tissue is important in controlling its overall growth and
these factors may, therefore, also prove useful in an assessment of
a patient’s prognosis.
Information related to cell kinetics can be a useful adjunct in
understanding the behaviour of tumours. In a variety of malignant
neoplasms, correlations have been noted between proliferation,
recurrence and overall survival (Hall et al, 1990). Different
methods have been used to study cell kinetics in tumour samples.
Methods for assessing the proliferative activity in vitro or in vivo
required labelling with [3H]-thymidine, cytometry to examine the
relative cellular DNA content and the application of immunohisto-
chemical techniques. The current study determined the prolifera-
tive activity of the carcinomas with immunohistochemistry by
using antibodies against the proteins PCNA, cyclin A, cyclin D,
cdk2, cdk4 and by measuring the cell cycle with flow cytometry.
Experiments using antisense oligonucleotides suggest that the
gene coding for PCNA is essential for cellular DNA synthesis
(Jaskulski et al, 1988). In the present investigation, we found that
patients who had lung tumours with a high proportion of PCNA-
positive cells exhibited shorter median survival times (51 weeks)
than did lung tumour patients with a low proportion of PCNA-
positive cells (89 weeks). Our finding agrees with the data reported
by Ebina et al (1994). Cyclin A has also been reported to be
involved in proliferation (Zindy et al, 1992). Along with other
researchers, we could demonstrate that cyclin A expression closely
correlates with the proportion of S phase cells as measured by flow
cytometry (Paterlini, 1995; Volm et al, 1997a). The current study
shows that patients with cyclin A-positive carcinomas have shorter
survival times than those with cyclin A-negative carcinomas.
Following mitogenic stimulation, cells in the late G1 phase exhibit
a rapid increase in the level of cyclin D (Tam et al, 1994). Cyclin
D1 is overexpressed in several types of tumours, because of gene
amplification or chromosomal rearrangement (Keyomarsi and
Pardee, 1993). However, the reported data on the prognostic value
of cyclin D1 are inconsistent (Michalides et al, 1995; Naitoh et al,
1995; Sheshadri et al, 1996). In an earlier study (Volm et al, 1996),
we found that the take rate of human squamous cell lung
carcinomas in nude mice was significantly higher when the carci-
nomas expressed cyclin D1. In the present investigation, we did
not observe a relationship between the expression of cyclin D1 and
patient outcome. It is postulated that the complexes formed by
cyclin D1 and cdk4 govern G1 progression and that cyclin A/cdk2
regulates progression through the S phase (Cordon-Cardo, 1995).
In our study, patients with cdk2-positive and cdk4-positive carci-
nomas had shorter overall survival times, but the differences
between cdk-positive and cdk-negative groups were statistically
insignificant. In short, we found a relationship between patient
survival and the investigated proliferative factors as measured
by immunohistochemistry. These results were confirmed by 
determining the S phases with flow cytometry.
Tumours remain dormant when tumour cell proliferation is
counterbalanced by an equivalent rate of cell death. The Fas
receptor/Fas ligand system and caspase-3 are primarily responsible
for the induction of apoptosis. To analyse the relationship between
the clinical outcome and apoptosis, the expression of these three
factors was, therefore, analysed by immunohistochemistry. Our
results show that the survival times were longer both in patients
with Fas-positive and Fas ligand-positive carcinomas. This is also
true for patients with caspase-3-positive carcinomas. Kangas et al
(1998) found that caspase-3 plays an important role in c-Myc-
induced apoptosis. Caspases are key effectors of cellular death
and, of the various caspases, caspase-3 is the one that so far best
correlates with apoptosis (Nicholson et al 1995). We could not find
a correlation between apoptotic index (TUNEL-assay) and the
survival time of patients (data not shown). This can be explained
with data reported by Kangas et al (1998). Apoptotic cells are
rapidly phagocytized and therefore, the evaluation of the apoptotic
index is limited and may underestimate the number of apoptotic
cells. Further, the TUNEL-assay can only detect apoptotic cells at
a late stage, therefore, the relationships of the expression of pro-
apoptotic factors and apoptotic indices that are detected at an
earlier stage are rather weak.
In order to determine whether a combination of the proliferative
and apoptotic factors may result in improved prognostic information,
Proliferative and apoptotic factors in lung cancer 1753
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Figure 7 Survival times of patients (Kaplan–Meier estimates) with NSCLCs
according to the expression of a proliferative (cdk4) and an apoptotic factor
(Fas)
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Figure 8 Survival times of patients (Kaplan–Meier estimates) with NSCLCs
according to the expression of a proliferative (S phases) and an apoptotic
factor (Fas)we examined all possible combinations of the investigated factors.
This systematic undertaking which also assessed stage and lymph
node involvement indicated that stage, lymph node status, Fas,
PCNA and cyclin A are the most important prognostic factors for
the clinical outcome of patients with non-small cell lung carci-
nomas. The pair FAS and PCNA yield the best prognostic separa-
tion along with stage or lymph node status. Proliferation and
apoptosis are under complex molecular control and both can be
triggered by diverse signals. By limiting the supply of such
signals, tight control can be exerted over cell numbers. If the rate
of cell death exceeds the proliferation rate, tumour regression will
occur. Conversely, if proliferation exceeds cell death, tumour
progression will result. Our results indicate that both cellular
proliferation and cell loss must be determined and that an evalua-
tion of the proliferation to apoptosis ratio may very well be more
important than the isolated assessment of either.
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